Eli Lilly & Co.

LLYNYSE

Healthcare · Pharmaceutical Preparations

Market cap

$896.13B

Employees

50,000

Exchange

NYSE

Headquarters

INDIANAPOLIS, IN

About Eli Lilly & Co.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Industry

Pharmaceutical Preparations

Sector

Healthcare

Country

Website

www.lilly.com

LLY news

Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations

Benzinga · Jun 1, 2026

Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors

The Motley Fool · May 30, 2026

From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook

Eli Lilly's latest clinical results for its oral GLP-1 candidate Retatrutide demonstrate promising efficacy and safety profiles, supporting the company's expansion beyond its injectable Zepbound product. The data strengthens Lilly's competitive position in the rapidly growing weight-loss and diabetes treatment market, as investors seek alternatives to existing GLP-1 therapies.

Investing.com · May 21, 2026

View full LLY analysis →